Aetna modified CPB 0356 for meningococcal vaccines, effective December 20, 2025. Here's what changes for billing teams.
Aetna, a CVS Health company, updated its meningococcal vaccine coverage policy under CPB 0356 to align with the latest CDC Advisory Committee on Immunization Practices (ACIP) recommendations. This update expands covered indications and adds newer vaccine formulations — including pentavalent vaccines Penbraya and Penmenvy — affecting CPT codes 90619, 90620, 90621, 90623, 90624, 90644, 90733, and 90734. If your practice or health system administers meningococcal vaccines to adolescents, immunocompromised patients, or high-risk populations, this policy change affects your reimbursement and claim documentation requirements now.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Meningococcal Vaccines — CPB 0356 |
| Policy Code | CPB 0356 |
| Change Type | Modified |
| Effective Date | December 20, 2025 |
| Impact Level | Medium |
| Specialties Affected | Pediatrics, Family Medicine, Internal Medicine, Infectious Disease, Travel Medicine, Occupational Health |
| Key Action | Audit charge capture for CPT 90623 and 90624 (pentavalent vaccines) and confirm ICD-10 diagnosis codes align with ACIP-approved indications before billing. |
Aetna Meningococcal Vaccine Coverage Criteria and Medical Necessity Requirements 2025
Aetna's meningococcal vaccine coverage policy under CPB 0356 follows CDC ACIP recommendations directly. Medical necessity is established when the vaccine type and patient indication match the criteria below. CPB 0356 does not reference a prior authorization process in the criteria reviewed — verify current authorization requirements directly with Aetna before billing. Coverage is criteria-based, meaning documentation is your primary defense against a claim denial.
MenACWY Vaccines (CPT 90619, 90734)
Aetna covers MenACWY vaccines — brand names Menactra, Menveo, and MenQuadfi — for routine adolescent vaccination and high-risk adults. The standard schedule is a single dose at age 11 or 12, followed by a booster at age 16. Adolescents who got their first dose between ages 13 and 15 get a booster at 16–18, with a minimum eight-week interval between doses.
Adolescents who receive their first dose after their 16th birthday do not need a booster. This is a common documentation gap — if a patient presents at 17 for a first dose, you do not bill for a future booster unless a new high-risk indication develops.
High-risk indications that qualify patients of any age (two months and older) for MenACWY include:
| # | Covered Indication |
|---|---|
| 1 | Anatomic or functional asplenia (including sickle cell disease — ICD-10 D57.00–D57.819) |
| 2 | First-year college students who are unvaccinated and living in residence halls (ICD-10 Z59.3) |
| 3 | Persistent complement deficiencies or use of complement inhibitors like eculizumab (Soliris) or ravulizumab (Ultomiris) |
| 4 | HIV infection (ICD-10 B20, Z21) |
| 5 | Meningococcal disease outbreak exposure (ICD-10 Z20.811) |
| 6 | Travel to hyperendemic or epidemic regions |
| 7 | Microbiologists with routine exposure to Neisseria meningitidis isolates |
| 8 | Military recruits (ICD-10 Z02.3, Z65.8) |
Booster intervals for ongoing high-risk patients: ages two through six get a booster three years after primary vaccination, then every five years. Ages seven and older get a booster five years after primary, then every five years. Document the original vaccination date — Aetna's criteria for booster medical necessity depends on time since primary vaccination.
MenB Vaccines (CPT 90620, 90621)
Serogroup B vaccines — Bexsero (CPT 90620, two-dose schedule) and Trumenba (CPT 90621, three-dose schedule) — have specific coverage criteria that differ from MenACWY. These are not interchangeable in documentation. Bill the code that matches the specific vaccine administered and the dose schedule.
High-risk indications for MenB include asplenia, complement deficiencies, complement inhibitor use, HIV, and outbreak exposure. The same ICD-10 codes apply. Adolescents and young adults aged 16 through 23 can receive MenB through shared clinical decision-making — this is a permissive coverage category, not a routine recommendation.
MenACWY + MenB Pentavalent Vaccines (CPT 90623, 90624)
This is where the 2025 update matters most for billing teams. CPB 0356 now explicitly covers pentavalent meningococcal vaccines — Penbraya (CPT 90623) and Penmenvy (CPT 90624). These combine MenACWY and MenB protection in a single vaccine series.
Penbraya (CPT 90623) uses a tetanus toxoid carrier and FHbp antigen. Penmenvy (CPT 90624) combines MenB-4C recombinant proteins with conjugated MenACWY components. If your practice has started administering these newer formulations, confirm your charge capture maps to CPT 90623 or 90624 specifically — not to the older MenACWY-only codes.
Catch-Up Vaccination
Members aged 19 through 21 who have not received a MenACWY dose after their 16th birthday can receive a single catch-up dose. Use ICD-10 Z23 (encounter for immunization) or the appropriate high-risk code if applicable. Use CPT 90734 for the intramuscular MenACWY formulation in this group.
Transplant Recipients
Aetna's code table for CPB 0356 includes ICD-10 codes Z94.0 through Z94.83 for solid organ transplant recipients — kidney (Z94.0), heart (Z94.1), lung (Z94.2), heart-lung (Z94.3), liver (Z94.4), intestine (Z94.82), and pancreas (Z94.83) — suggesting these patients may qualify under the high-risk pathway. Confirm the applicable indication and document accordingly. Review the full policy text for transplant-specific criteria before billing.
Aetna Meningococcal Vaccine Exclusions and Non-Covered Indications
CPB 0356 does not broadly exclude vaccines — the policy is permissive by design, following ACIP guidance. However, coverage is limited to CDC ACIP-approved indications. Vaccinations administered outside the approved schedule, for unapproved age groups, or without a documented indication will not meet medical necessity criteria.
The shared clinical decision-making pathway for MenB in patients aged 16–23 is not a blanket coverage guarantee. Aetna covers it under that framework, but documentation of the clinical discussion is part of establishing medical necessity. If your providers aren't documenting the shared decision-making conversation, claims in this population are exposure.
Coverage Indications at a Glance
| Indication | Status | Vaccine Type | Key CPT Codes | Notes |
|---|---|---|---|---|
| Routine adolescent vaccination (ages 11–18) | Covered | MenACWY | 90619, 90734 | Single dose at 11–12, booster at 16 |
| Catch-up vaccination (ages 19–21) | Covered | MenACWY | 90734 | One dose if not vaccinated after age 16 |
| Asplenia (anatomic or functional, including sickle cell) | Covered | MenACWY, MenB, Pentavalent | 90619, 90620, 90621, 90623, 90624, 90734 | Boosters required per schedule |
| Complement deficiency or complement inhibitor use | Covered | MenACWY, MenB, Pentavalent | 90619, 90620, 90621, 90623, 90624, 90734 | Includes eculizumab, ravulizumab users |
| HIV infection | Covered | MenACWY, MenB, Pentavalent | 90619, 90620, 90621, 90623, 90624, 90734 | ICD-10 B20 or Z21 |
| First-year college students in residence halls (unvaccinated) | Covered | MenACWY | 90619, 90734 | No booster required unless new risk |
| Outbreak exposure | Covered | MenACWY, MenB | 90619, 90620, 90621, 90734 | Single booster if interval met |
| Travel to hyperendemic regions | Covered | MenACWY | 90619, 90734 | Booster every 5 years for ongoing risk |
| Military recruits | Covered | MenACWY | 90619, 90734 | Booster every 5 years per high-risk travel |
| Microbiologists (routine N. meningitidis exposure) | Covered | MenACWY | 90619, 90734 | Booster every 5 years |
| Solid organ transplant recipients | Covered (verify criteria) | MenACWY, MenB, Pentavalent | 90619, 90620, 90621, 90623, 90624, 90734 | ICD-10 Z94.0–Z94.83 included in code table; review full policy for transplant-specific criteria |
| Adolescents and young adults 16–23 (shared clinical decision-making) | Covered | MenB | 90620, 90621 | Document shared decision-making conversation |
| Hib-MenCY combined vaccine (high-risk infants/toddlers) | Covered | Hib-MenCY | 90644 | For high-risk infants per ACIP criteria; verify age-specific thresholds in full policy text |
| Polysaccharide vaccine (subcutaneous) | Covered | MPSV4 | 90733 | For subcutaneous use; typically for specific populations |
| Pentavalent combination vaccines | Covered | MenABCWY | 90623, 90624 | New explicit coverage in CPB 0356 update |
Aetna Meningococcal Vaccine Billing Guidelines and Action Items 2025
The effective date for CPB 0356 is December 20, 2025. These action items apply now.
| # | Action Item |
|---|---|
| 1 | Add CPT 90623 and 90624 to your charge capture if you administer Penbraya or Penmenvy. These pentavalent vaccines are now explicitly covered under the updated Aetna meningococcal vaccine billing guidelines. If your charge master doesn't include them, you're either not billing or billing the wrong code. |
| 2 | Map your ICD-10 codes to specific patient indications before claims go out. Aetna's coverage policy ties every indication to a patient risk factor. Use Z23 for routine immunization encounters. Use condition-specific codes — B20 for HIV, D57.00–D57.819 for sickle cell, Q89.01 for congenital asplenia, D84.1 for complement deficiency — when the indication is medical rather than routine. |
| 3 | Audit your college student vaccination claims. First-year students in residence halls qualify under the high-risk pathway. Use Z59.3 (problems related to living in a residential institution). This is a specific carve-out in the policy — but it only covers the initial series, not boosters, unless a new risk factor develops. |
| 4 | Check booster timing documentation for high-risk patients. Aetna's booster criteria are time-based. For patients under age seven, the first booster is due three years after primary vaccination. For patients seven and older, it's five years. If your practice manages ongoing high-risk patients, build a flag in your system to confirm booster eligibility before billing. |
| 5 | Document shared clinical decision-making for MenB in patients aged 16–23. This group gets permissive coverage, not routine coverage. The clinical note needs to show that the provider and patient discussed the risks and benefits. Without that documentation, a claim denial is likely. Pull a sample of recent MenB claims for this age group and confirm the notes support the billing. |
| 6 | Confirm immunization administration code 90471 is on every vaccine claim. CPT 90471 covers the administration itself and must appear alongside the vaccine product code. It's easy to miss on high-volume vaccine days. Run a quick audit of recent meningococcal vaccine claims and confirm 90471 is attached. |
| 7 | For transplant patients, review the full CPB 0356 policy text before billing. Aetna's code table includes Z94.0 through Z94.83 for solid organ transplant recipients, but the available source does not confirm the specific coverage criteria for this population. Confirm the applicable indication with Aetna and document accordingly before submitting claims for these patients. |
If you bill vaccines across a complex payer mix or have a large immunocompromised population, loop in your compliance officer before December 20, 2025 to make sure your documentation workflows match the updated criteria.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Meningococcal Vaccines Under CPB 0356
Covered CPT Codes (When Selection Criteria Are Met)
| Code | Description |
|---|---|
| 90619 | Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, tetanus toxoid carrier (MenACWY-TT), for intramuscular use |
| 90620 | Meningococcal recombinant protein and outer membrane vesicle vaccine, serogroup B, 2-dose schedule, for intramuscular use (Bexsero) |
| 90621 | Meningococcal recombinant lipoprotein vaccine, serogroup B, 3-dose schedule, for intramuscular use (Trumenba) |
| 90623 | Meningococcal pentavalent vaccine, conjugated MenA, C, W, Y-tetanus toxoid carrier, and MenB-FHbp, for intramuscular use (Penbraya) |
| 90624 | Meningococcal pentavalent vaccine, MenB-4C recombinant proteins and outer membrane vesicle and conjugated MenACWY, for intramuscular use (Penmenvy) |
| 90644 | Meningococcal conjugate vaccine, serogroups C & Y and Haemophilus influenzae type b vaccine (Hib-MenCY), for intramuscular use |
| 90733 | Meningococcal polysaccharide vaccine, serogroups A, C, Y, W-135, quadrivalent (MPSV4), for subcutaneous use |
| 90734 | Meningococcal conjugate vaccine, serogroups A, C, Y and W-135, quadrivalent (MenACWY), for intramuscular use |
Key ICD-10-CM Diagnosis Codes
| Code | Description |
|---|---|
| B20 | Human immunodeficiency virus [HIV] disease |
| D57.00–D57.819 | Sickle-cell disorders |
| D84.1 | Defects in the complement system |
| D89.89 | Other specified disorders involving the immune mechanism, not elsewhere classified |
| Q89.01 | Asplenia (congenital) |
| Z01.84 | Encounter for antibody response examination (monitoring meningococcal vaccine responses) |
| Z02.1 | Encounter for pre-employment examination |
| Z02.3 | Encounter for examination for recruitment to armed forces |
| Z02.89 | Encounter for other administrative examinations |
| Z20.811 | Contact with and suspected exposure to meningococcus |
| Z20.89 | Contact with and suspected exposure to other communicable diseases |
| Z21 | Asymptomatic HIV infection status |
| Z23 | Encounter for immunization |
| Z59.3 | Problems related to living in a residential institution |
| Z65.8 | Other specified problems related to psychosocial circumstances (military deployment status) |
| Z79.810–Z79.818 | Acquired absence of spleen (note: source policy lists these codes with "Acquired absence of spleen" as the description; verify against current ICD-10-CM tabular if codes appear inconsistent) |
| Z90.81 | Acquired absence of spleen |
| Z94.0 | Kidney transplant status |
| Z94.1 | Heart transplant status |
| Z94.2 | Lung transplant status |
| Z94.3 | Heart and lungs transplant status |
| Z94.4 | Liver transplant status |
| Z94.82 | Intestine transplant status |
| Z94.83 | Pancreas transplant status |
Get the Full Picture for CPT 90623
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.